针对EGFR T790M的新型突变选择性EGFR激酶抑制剂
Wenjun Zhou1, Dalia Ercan, Liang Chen
1Department of Cancer Biology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts 02115, USA.
新的协同胺抑制剂在非小细胞肺癌中对EGFR T790M突变具有高强度,为现有治疗提供了潜在的替代方案,具有提高选择性和降低毒性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 表皮生长因子受体 (EGFR) 激酶抑制剂对于治疗EGFR突变非小细胞肺癌 (NSCLC) 至关重要.
- 耐药性,特别是T790M突变,限制了当前EGFR抑制剂的临床疗效.
- 现有的基纳林基抑制剂向野生型EGFR,导致毒性和对抗耐药突变的有限成功.
研究的目的:
- 确定具有对T790M耐药性突变高选择性的新型EGFR抑制剂.
- 开发一种新的共价抑制剂类别,克服NSCLC中的抵抗机制.
- 探索替代基架,以传统的基纳林EGFR抑制剂.
主要方法:
- 对EGFR T790M的不可逆转酶抑制剂库的选.
- 在体外生化测试以确定对突变和野生型EGFR的效力.
- 在EGFR T790M驱动肺癌的小鼠模型中的体内疗效研究.
- 同结晶研究以阐明抑制的结构基础.
主要成果:
- 与基纳林基抑制剂相比,对EGFR T790M具有30至100倍更大的功效的共价胺EGFR抑制剂的鉴定.
- 这些新型抑制剂在体外显示出对野生型EGFR的功效降低了100倍.
- 在由EGFR T790M突变驱动的肺癌的临床前小鼠模型中证明有效性.
结论:
- 协同胺抑制剂代表了一个新型的突变选择性不可逆转的EGFR激酶抑制剂.
- 与现有的基纳林药物相比,这些药物显示出改善临床疗效和更好的耐受性的潜力.
- 对突变激酶的功能查是发现新型选择性激酶抑制剂的强大策略.
更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
15:05Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
相关概念视频
Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Mitogens and the Cell Cycle
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
